Navigation Links
Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
Date:6/20/2008

RICHMOND, Va., June 20 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it intends to request a hearing before The NASDAQ Listing Qualifications Panel ('the Panel") to appeal an earlier Staff Determination to delist the Company's common stock from The NASDAQ Capital Market.

Insmed received a letter from The NASDAQ Stock Market ("NASDAQ") on June 17, 2008 indicating that the Company had not regained compliance with NASDAQ's minimum bid price requirement of $1.00 per share for continued listing of Insmed's common stock on The NASDAQ Capital Market as set forth in Marketplace Rule 4310(c)(4) (the "Staff Determination"). As a result, the Company's common stock would be subject to delisting unless Insmed requests a hearing before the Panel. Following procedures set forth in The NASDAQ Marketplace Rule 4800 series; the Company intends to request a hearing before the Panel to review the Staff Determination. The hearing request will stay the delisting of Insmed's common stock, pending the decision of the Panel following the hearing, allowing the Company's common stock to continue to trade on The NASDAQ Capital Market. There can be no assurance, however, that the Panel will grant Insmed's request for continued listing of its common stock on The NASDAQ Capital Market.

In the event that the Panel determines not to grant the Company's request for continued listing of its common stock on The NASDAQ Capital Market, Insmed's common stock may become eligible for quotation and trading on the OTC Bulletin Board.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Announces First Quarter 2008 Financial Results
2. Insmed to Present at CBI Follow-On Biologics Conference
3. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
4. Insmed Announces Additional Information in Compliance With NASDAQ Rules
5. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
6. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
7. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
10. Insmed to Appeal Delisting Notification From Nasdaq
11. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced ... and the Department of Defense has announced the award of a new Advanced ...
(Date:1/18/2017)... IL (PRWEB) , ... January 18, 2017 , ... ... on January 24th, 2017, to sell research and genetic testing lab equipment from ... service in the Northwest and Northeast regions of the United States. This 1-day ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  HUYA Bioscience ... of China,s pharmaceutical innovations, announced ... of Sciences Innovation and Investment Company (referred to as ... commercializing biomedical innovations discovered by leading scientists at CAS ... world. HUYA is the first company to ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® SP2 ... base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal delta” ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
Breaking Biology News(10 mins):